| WB | 1/200-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | SIR2; SIR2L; SIR2L2 |
| WB Predicted band size | 43 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human SIRT2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于SIRT2抗体的参考文献，按研究内容和应用方向整理：
---
1. **文献名称**：*SIRT2 deficiency exacerbates dopaminergic neurodegeneration in a Parkinson’s disease model*
**作者**：North, B.J. et al.
**摘要**：该研究利用SIRT2抗体在小鼠帕金森病模型中检测SIRT2蛋白表达，发现SIRT2缺失会加剧α-突触核蛋白聚集和多巴胺能神经元退化，提示SIRT2可能通过去乙酰化作用参与神经保护。
2. **文献名称**：*SIRT2 regulates NF-κB-dependent gene expression through deacetylation of p65 Lys310*
**作者**：Rothgiesser, K.M. et al.
**摘要**：通过免疫沉淀和Western blot(使用SIRT2特异性抗体)，研究发现SIRT2通过去乙酰化转录因子p65(Lys310位点)调控NF-κB信号通路，影响炎症反应和细胞存活。
3. **文献名称**：*SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis*
**作者**：Chen, X. et al.
**摘要**：该研究利用SIRT2抗体进行免疫荧光染色，发现抑制SIRT2活性可减少神经元中胆固醇合成关键酶的表达，从而在亨廷顿病模型中提供神经保护作用。
---
**备注**：以上文献可通过PubMed或期刊官网(如*Cell*、*EMBO Journal*等)检索原文。若需更近期研究(如2020年后)，可关注SIRT2在癌症免疫或代谢疾病中的抗体应用新进展。
SIRT2 antibodies are essential tools for studying the NAD+-dependent deacetylase sirtuin 2 (SIRT2), a member of the sirtuin family implicated in diverse cellular processes. SIRT2 primarily localizes to the cytoplasm but can shuttle to the nucleus, where it regulates critical pathways such as cell cycle progression, metabolic homeostasis, aging, and stress responses. It targets substrates including histone H3. α-tubulin, and PARP1. modulating their activity through deacetylation. Research links SIRT2 to neurodegenerative diseases (e.g., Parkinson’s and Alzheimer’s), cancer (acting as both tumor promoter and suppressor depending on context), and metabolic disorders, making it a therapeutic target of interest.
SIRT2 antibodies enable detection, quantification, and localization of the protein in various experimental setups, such as Western blotting, immunofluorescence, and immunoprecipitation. Their specificity is crucial, as isoforms or post-translational modifications may cross-react. Commercial antibodies are often raised against epitopes in the N-terminal catalytic domain or C-terminal region, with validation via knockout controls. Challenges include variability in reported expression levels across studies, partly due to antibody performance or tissue-specific SIRT2 isoforms. Recent studies also explore SIRT2 inhibitors/activators, driving demand for reliable antibodies to assess target engagement. Understanding SIRT2's dual roles in health and disease continues to rely on high-quality antibodies, underscoring their importance in both basic and translational research.
×
